Breast and Prostate Cancer: More Similar Than Different

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2010 Feb 12

PMID 20147902

Citations 111

Authors

Gail P Risbridger

Ian D Davis

Stephen N Birrell

Wayne D Tilley

Affiliations

Soon will be listed here.

Abstract

Breast cancer and prostate cancer are the two most common invasive cancers in women and men, respectively. Although these cancers arise in organs that are different in terms of anatomy and physiological function both organs require gonadal steroids for their development, and tumours that arise from them are typically hormone-dependent and have remarkable underlying biological similarities. Many of the recent advances in understanding the pathophysiology of breast and prostate cancers have paved the way for new treatment strategies. In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes.

Citing Articles

Chemogenomics for steroid hormone receptors (NR3).

Schallmayer E, Isigkeit L, Elson L, Muller S, Knapp S, Marschner J Commun Chem. 2025; 8(1):29.

PMID: 39900826 PMC: 11790914. DOI: 10.1038/s42004-025-01427-z.

Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.

Li W, Shi X, Tan C, Jiang Z, Li M, Ji Z Nat Chem Biol. 2025; .

PMID: 39870764 DOI: 10.1038/s41589-024-01826-8.

Harnessing sample preparation for RNA-sequencing toward a reliable bioinformatics analysis.

Talia M, Cesario E, Cirillo F, Scordamaglia D, Di Dio M, Zicarelli A J Transl Med. 2024; 22(1):846.

PMID: 39285433 PMC: 11406772. DOI: 10.1186/s12967-024-05585-x.

Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.

Chang J, Suraju M, Tran C, Chan C, Ear P, Howe J J Surg Res. 2024; 302:53-63.

PMID: 39083906 PMC: 11490409. DOI: 10.1016/j.jss.2024.07.012.

ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.

Zamora I, Gutierrez M, Pascual A, Pajares M, Barajas M, Perez L Cell Oncol (Dordr). 2024; 48(1):83-99.

PMID: 38819630 PMC: 11850477. DOI: 10.1007/s13402-024-00957-3.

References

Liu X, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C . Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun. 2002; 290(1):249-55. DOI: 10.1006/bbrc.2001.6188. View

Speirs V . The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res. 2008; 10(5):111. PMC: 2614506. DOI: 10.1186/bcr2140. View

Edwards D, Chamness G, McGuire W . Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta. 1979; 560(4):457-86. DOI: 10.1016/0304-419x(79)90013-1. View

Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G . IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol. 2004; 172(9):5467-77. DOI: 10.4049/jimmunol.172.9.5467. View

Jefford M, Maraskovsky E, Cebon J, Davis I . The use of dendritic cells in cancer therapy. Lancet Oncol. 2002; 2(6):343-53. DOI: 10.1016/s1470-2045(00)00389-2. View

Shin S, Verma I . BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc Natl Acad Sci U S A. 2003; 100(12):7201-6. PMC: 165853. DOI: 10.1073/pnas.1132020100. View

Taylor R, Risbridger G . Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets. 2008; 8(6):490-7. DOI: 10.2174/156800908785699351. View

Birrell S, Butler L, Harris J, Buchanan G, Tilley W . Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007; 21(10):2285-93. DOI: 10.1096/fj.06-7518com. View

Zhu P, Baek S, Bourk E, Ohgi K, Garcia-Bassets I, Sanjo H . Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell. 2006; 124(3):615-29. DOI: 10.1016/j.cell.2005.12.032. View

10.

Graham J, Clarke C . Physiological action of progesterone in target tissues. Endocr Rev. 1997; 18(4):502-19. DOI: 10.1210/edrv.18.4.0308. View

11.

McPherson S, Ellem S, Simpson E, Patchev V, Fritzemeier K, Risbridger G . Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 2006; 148(2):566-74. DOI: 10.1210/en.2006-0906. View

12.

Zheng S, Liu W, Wiklund F, Dimitrov L, Balter K, Sun J . A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate. 2006; 66(14):1556-64. DOI: 10.1002/pros.20496. View

13.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

14.

de Jong P, van de Ven J, Nortier H, Donker T, Thijssen J, Slee P . Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res. 1997; 57(11):2109-11. View

15.

Santen R, Brodie H, Simpson E, Siiteri P, Brodie A . History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009; 30(4):343-75. DOI: 10.1210/er.2008-0016. View

16.

Iorns E, Turner N, Elliott R, Syed N, Garrone O, Gasco M . Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 2008; 13(2):91-104. DOI: 10.1016/j.ccr.2008.01.001. View

17.

Swarbrick A, Lee C, Sutherland R, Musgrove E . Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol. 2000; 20(7):2581-91. PMC: 85474. DOI: 10.1128/MCB.20.7.2581-2591.2000. View

18.

Fleming F, Myers E, Kelly G, Crotty T, McDermott E, OHiggins N . Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol. 2004; 57(10):1069-74. PMC: 1770462. DOI: 10.1136/jcp.2004.016733. View

19.

Zhu X, Mulcahy L, Mohammed R, Lee A, Franks H, Kilpatrick L . IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008; 10(6):R95. PMC: 2656888. DOI: 10.1186/bcr2195. View

20.

Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I . Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. Breast Cancer. 2009; 17(4):254-60. DOI: 10.1007/s12282-009-0148-2. View